Patents by Inventor Chijian ZUO

Chijian ZUO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230279389
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule and an application thereof in preparation of a circular RNA, and in particular, to a recombinant nucleic acid molecule for preparing a circular RNA, a recombinant expression vector, a circular RNA, a composition, a method for preparing a circular RNA, a method for expressing a target polypeptide in a cell, a method for screening a target coding region sequence, a system for screening a target coding region sequence, and a method for screening a ribozyme recognition site sequence.
    Type: Application
    Filed: July 22, 2022
    Publication date: September 7, 2023
    Inventors: Zonghao QIU, Qiangbo HOU, Yang ZHAO, Chijian ZUO, Zhenhua SUN
  • Publication number: 20230279407
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule based on point mutation of translation initiation element and use thereof in the preparation of circular RNA, and in particular to a recombinant nucleic acid molecule for preparing circular RNA, a recombinant expression vector, circular RNA, a composition, a method for preparing circular RNA, a method for expressing a target polypeptide in a cell, a method for preventing or treating a disease, a method for editing a translation initiation element sequence, and a system for editing a translation initiation element sequence.
    Type: Application
    Filed: July 22, 2022
    Publication date: September 7, 2023
    Inventors: Qiangbo HOU, Zonghao QIU, Yang ZHAO, Chijian ZUO, Zhenhua SUN
  • Patent number: 11634727
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA and its application in protein expression. Specifically, the present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA, recombinant expression vector, pre-circularized RNA, circular RNA, recombinant host cell, pharmaceutical composition and protein preparing method. The transcription product of the recombinant nucleic acid molecule in this present disclosure is a circular RNA which containing specific IRES element. IRES element can increase the protein expression level of circular RNA in eukaryotic cells, achieve efficient and persistent expression of protein. It has important application value in many fields like: Preparation of mRNA infectious disease vaccines, therapeutic mRNA tumor vaccines, mRNA-based dendritic cell tumor vaccines, mRNA-based gene therapy, mRNA-based chimeric antigen receptor T cell therapy, and protein supplement therapy.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: April 25, 2023
    Assignee: Purecodon (Hong Kong) Biopharma Ltd.
    Inventors: Zhenhua Sun, Chijian Zuo, Jiafeng Zhu
  • Publication number: 20230119715
    Abstract: The disclosure belongs to the technical field of bioinformatics and bioengineering, and specifically, relates to a Levenshtein distance-based IRES screening method, a polynucleotide screened based on this method, a circular nucleic acid molecule including the polynucleotide, a cyclization precursor nucleic acid molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, and use. In the disclosure, averages of Levenshtein distances between all sample sequences and to-be-predicted sequences are compared, to efficiently and accurately determine whether there is an IRES in the to-be-predicted sequence, which has advantages of high efficiency and an accurate screening result.
    Type: Application
    Filed: October 12, 2022
    Publication date: April 20, 2023
    Inventors: Qiangbo HOU, Jiafeng ZHU, Zonghao QIU, Chijian ZUO, Zhenhua SUN
  • Publication number: 20230060661
    Abstract: The present disclosure belongs to the technical field of bio-medicine, particularly, the present disclosure relates to a tissue-specifically expressed circular RNA molecule, a cyclization precursor RNA molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, a composition, a pharmaceutical preparation and application thereof in preparation of a drug for preventing or treating diseases, as well as a method for preventing or treating diseases. The circular RNA molecule provided by the present disclosure operably links a coding region to an expression regulatory element, realizing specific high expression of a target polypeptide in target cells or target tissues, and low expression of the target polypeptide in non-target cells or non-target tissues, and having high tissue expression specificity, thereby providing a safe and effective treatment strategy for clinical targeted therapy of diseases such as tumors.
    Type: Application
    Filed: August 10, 2022
    Publication date: March 2, 2023
    Inventors: Chijian ZUO, Zonghao QIU, Jiali YANG, Jiafeng ZHU, Na LI, Zhenhua SUN
  • Publication number: 20230042694
    Abstract: The present disclosure belongs to the field of biomedicine. Specifically, the present disclosure relates to a circular RNA molecule, a cyclization precursor RNA molecule, a recombinant nucleic acid molecule, a recombinant expression vector, a recombinant host cell, a composition and use thereof in targeted degradation of a protein of interest, as well as a method for preventing or treating a disease. The circular RNA molecule has good membrane permeability, is easily delivered into cells, and has high-efficiency in vivo protein targeted degradation activity. The circular RNA molecule of the present disclosure successfully achieves inhibition of tumor growth, which proves the in vivo protein degradation activity of bio-PROTACs for the first time, and provides a positive and effective treatment solution for the treatment of diseases such as tumor.
    Type: Application
    Filed: July 26, 2022
    Publication date: February 9, 2023
    Inventors: Chijian ZUO, Jiali YANG, Jiafeng ZHU, Yaran DU, Yang ZHAO, Zhenhua SUN
  • Publication number: 20220177908
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA and its application in protein expression. Specifically, the present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA, recombinant expression vector, pre-circularized RNA, circular RNA, recombinant host cell, pharmaceutical composition and protein preparing method. The transcription product of the recombinant nucleic acid molecule in this present disclosure is a circular RNA which containing specific IRES element. IRES element can increase the protein expression level of circular RNA in eukaryotic cells, achieve efficient and persistent expression of protein. It has important application value in many fields like: Preparation of mRNA infectious disease vaccines, therapeutic mRNA tumor vaccines, mRNA-based dendritic cell tumor vaccines, mRNA-based gene therapy, mRNA-based chimeric antigen receptor T cell therapy, and protein supplement therapy.
    Type: Application
    Filed: June 3, 2021
    Publication date: June 9, 2022
    Inventors: Zhenhua SUN, Chijian ZUO, Jiafeng ZHU
  • Publication number: 20220177910
    Abstract: The present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA and its application in protein expression. Specifically, the present disclosure relates to a recombinant nucleic acid molecule of the transcriptional circular RNA, recombinant expression vector, pre-circularized RNA, circular RNA, recombinant host cell, pharmaceutical composition and protein preparing method. The transcription product of the recombinant nucleic acid molecule in this present disclosure is a circular RNA which containing specific IRES element. IRES element can increase the protein expression level of circular RNA in eukaryotic cells, achieve efficient and persistent expression of protein. It has important application value in many fields like: Preparation of mRNA infectious disease vaccines, therapeutic mRNA tumor vaccines, mRNA-based dendritic cell tumor vaccines, mRNA-based gene therapy, mRNA-based chimeric antigen receptor T cell therapy, and protein supplement therapy.
    Type: Application
    Filed: September 27, 2021
    Publication date: June 9, 2022
    Inventors: Zhenhua SUN, Chijian ZUO, Jiafeng ZHU